ARCHIVES

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: James Wallace Named CALGB Executive Officer; Gritz Receives First Joseph Cullen Award

September 11, 1992

Selumetinib Displays Positive Results, 60% with Stable Disease

April 29, 2011

FDA Approves Taxotere For Node+ Breast Cancer

August 27, 2004

SWOG Wins NCI Grant Renewal For Six Years

April 16, 2010

DCE Board Approves Concept For New $850,000 Year Grant Program To Study Viruses In Cervical Cancer

November 9, 1984

Toxic Wastes And Cancer Linked; NCI Data Questioned In Bay Study

December 13, 1985